Eighteen-Year Follow-Up of GD2 Chimeric Antigen Receptor-Cytotoxic T Lymphocyte Therapy in Patients with Neuroblastoma

被引：0

作者：

Li, Che-Hsing ^{[1
,2
,3
]}

Sharma, Sandhya ^{[1
]}

Heczey, Andras ^{[1
,3
]}

Louis, Chrystal ^{[1
]}

Steffin, David ^{[1
,3
]}

Grilley, Bambi ^{[1
,4
]}

Thakkar, Sachin ^{[1
]}

Wu, Mengfen ^{[4
]}

Wang, Tao ^{[4
]}

Rooney, Cliona ^{[1
,4
]}

Brenner, Malcolm ^{[1
,4
]}

Heslop, Helen ^{[1
,4
]}

机构：

[1] Houston Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA

[2] Baylor Coll Med, Program Immunol & Microbiol, Houston, TX USA

[3] Baylor Coll Med, Dept Pediat, Ctr Adv Innate Cell Therapy, Houston, TX USA

[4] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX USA

来源：

MOLECULAR THERAPY | 2024年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

243.

引用

页码：130 / 131

页数：2

共 50 条

[31] A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Dongjian
Zhu, Yu
Chen, Zhi
Jiang, Songfu
He, Haiyan
Qiang, Wanting
Xiang, Fang
Sun, Xuedong
Du, Juan
CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3747 - 3756
[32] Eighteen-year follow-up cohort study on hepatitis B and C virus infections related long-term prognosis among hemodialysis patients in Hiroshima
Ko, Ko
Nagashima, Shintaro
Yamamoto, Chikako
Takahashi, Kazuaki
Matsuo, Junko
Ohisa, Masayuki
Akita, Tomoyuki
Matyakubov, Jamshid
Mirzaev, Ulugbek
Katayama, Keiko
Masaki, Takao
Tanaka, Junko
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3436 - 3447
[33] 4SCAR-GD2-modified T-cell therapy in neuroblastoma with MYCN amplification: A case report with over 4-year follow-up data
Xu, Xiao
Zhao, Wen
Yue, Zhixia
Qin, Maoquan
Jin, Mei
Chang, Lung-Ji
Ma, Xiaoli
PEDIATRIC INVESTIGATION, 2020, 4 (01) : 55 - 58
[34] Eradication of neuroblastoma by T-cells redirected with an optimized GD2-specific chimeric antigen receptor and IL-15
Chen, Yuhui
Sun, Chuang
Metelitsa, Leonid
Dotti, Gianpietro
Savoldo, Barbara
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
[35] 2 YEAR FOLLOW-UP OF ADALIMUMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE
Kemp, K.
Dibb, M.
Makin, A. J.
Campbell, S. S.
GUT, 2009, 58 : A64 - A64
[36] Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
Gargett, Tessa
Brown, Michael P.
CYTOTHERAPY, 2015, 17 (04) : 487 - 495
[37] Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
Jiayi Yu
Xiaowen Wu
Junya Yan
Huan Yu
Longwen Xu
Zhihong Chi
Xinan Sheng
Lu Si
Chuanliang Cui
Jie Dai
Meng Ma
Tianxiao Xu
Yan Kong
Jun Guo
Journal of Hematology & Oncology, 11
[38] Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
Yu, Jiayi
Wu, Xiaowen
Yan, Junya
Yu, Huan
Xu, Longwen
Chi, Zhihong
Sheng, Xinan
Si, Lu
Cui, Chuanliang
Dai, Jie
Ma, Meng
Xu, Tianxiao
Kong, Yan
Guo, Jun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[39] Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1
Vadgama, Sachin
Mann, Jess
Bashir, Zahid
Spooner, Clare
Collins, Graham P.
Bullement, Ash
VALUE IN HEALTH, 2022, 25 (06) : 1010 - 1017
[40] Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy
Korell, Felix
Schubert, Maria-Luisa
Sauer, Tim
Schmitt, Anita
Derigs, Patrick
Weber, Tim Frederik
Schnitzler, Paul
Mueller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
BLOOD, 2021, 138

← 1 2 3 4 5 →